

## References

I-220

1. Tepezza™ (teprotumumab-trbw), for injection, for intravenous use [package insert]. Horizon Therapeutics, Inc. Lake Forest, IL. 07/2023.
2. Clinical Pharmacology™ Compendium. 2024. Tampa FL: Gold Standard, Inc. Teprotumumab-trbw.
3. Micromedex DrugDex Compendium®. -2024. Teprotumumab-trbw.
4. Smith T, Kahaly G, Ezra D, et al. Teprotumumab for Thyroid-Associated Ophthalmopathy. *NEJM*. 2017;376:1748-1761.
5. Douglas R, Kahaly G, Patel A, et al. Teprotumumab for the Treatment of Active Thyroid Eye Disease. *NEJM*. 2020;382:341-352.
6. Mitchell A, Goss L, Mathiopoulou L, et al. Diagnosis of Graves' Orbitopathy (DiaGO): Results of a Pilot Study to Assess the Utility of an Office Tool for Practicing Endocrinologists. *J Clin Endocrinol Metab*. 2015;100(3):E458-E462.
7. Teprotumumab-trbw In: AHFS Drug Information Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists. Updated February 25, 2020.
8. MCGTM Care Guidelines, 22nd edition, 2018, Home Infusion Therapy, CMT: CMT-0009(SR).